Yu Li
Known title: VP Cntrllr/Prncpl Acctng OffcrCIK: 0001777275
Associated companies
Transaction History
| IMDX | ▲ Buy | Option Exercise | 25,000 | $0 | 5/18/2022 | View on chart |
| IMDX | ▼ Sell | Open Market | 8,128 | $9K | 5/18/2022 | View on chart |
| IMDX | ▲ Buy | Option Exercise | 25,000 | $0 | 5/18/2022 | View on chart |
| IMDX | ▼ Sell | Open Market | 8,128 | $9K | 5/18/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.